Emcure Pharmaceuticals Ltd vs Fabino Enterprises Ltd Stock Comparison
Emcure Pharmaceuticals Ltd vs Fabino Enterprises Ltd Stock Comparison
Last Updated on: May 03, 2026
Key Highlights
The Latest Trading Price of Emcure Pharmaceuticals Ltd is ₹ 1679 as of 30 Apr 15:30
. The P/E Ratio of Emcure Pharmaceuticals Ltd changed from 29.8 on March 2025 to 29.8 on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Fabino Enterprises Ltd changed from 600 on March 2023 to 84.5 on March 2025 . This represents a CAGR of -47.97% over 3 years The Market Cap of Emcure Pharmaceuticals Ltd changed from ₹ 20327 crore on March 2025 to ₹ 20327 crore on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Fabino Enterprises Ltd changed from ₹ 6.3 crore on March 2023 to ₹ 5.15 crore on March 2025 . This represents a CAGR of -6.50% over 3 years The revenue of Emcure Pharmaceuticals Ltd for the Dec '25 is ₹ 2365 crore as compare to the Sep '25 revenue of ₹ 2272 crore. This represent the growth of 4.06% The revenue of Fabino Enterprises Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Emcure Pharmaceuticals Ltd for the Dec '25 is ₹ 456.45 crore as compare to the Sep '25 ebitda of ₹ 478.6 crore. This represent the decline of -4.63% The ebitda of Fabino Enterprises Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Emcure Pharmaceuticals Ltd changed from ₹ 152.59 crore to ₹ 231.37 crore over 7 quarters. This represents a CAGR of 26.85%
The net profit of Fabino Enterprises Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0%
The Dividend Payout of Emcure Pharmaceuticals Ltd changed from 4.3 % on March 2021 to 17.92 % on March 2025 . This represents a CAGR of 33.04% over 5 yearsThe Dividend Payout of Fabino Enterprises Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .
About Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Limited was originally incorporated as Emcure Pharmaceuticals Private Limited', as a Private Company, pursuant to a Certificate of Incorporation dated April 16, 1981 issued by Registrar of Companies, Maharashtra at Bombay.
Subsequently, Company was converted into a Public Company and the name of Company was changed to Emcure Pharmaceuticals Limited', through a fresh Certificate of Incorporation issued by the RoC, Maharashtra in Pune on September 18, 2001.
Emcure Pharmaceuticals an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad
range of pharmaceutical products across several major therapeutic areas.
In India, they are present across acute and chronic therapeutic areas, and their key therapeutic areas include gynecology, cardiovascular, vitamins, minerals and nutrients, human immunodeficiency virus antivirals, blood-related and oncology/anti-neoplastics.
About Fabino Enterprises Ltd
Fabino Enterprises Limited is a growing pharmaceutical company promoted by Atul Kumar Jain.
The Company was incorporated as 'Fabino Life Sciences Private Limited' on October 27, 2011 with the Registrar of Companies, Delhi and Haryana.
Subsequently, the Company got converted to Public Limited Company and the name of Company was changed to 'Fabino Life Sciences Limited'.
A fresh Certificate of Incorporation was issued on March 21, 2015 by the Registrar of Companies, Delhi.
The Company operate in the business of manufacturing, marketing of pharmaceutical, allopathic, herbal, veterinary, and other consumer products like, packing, trading, etc.
The core business is marketing of pharmaceutical formulation & products in domestic market through its own distribution network and sales force under own brand name, getting Ayurvedic formulations manufactured through loan licensing facilities, packing, labeling etc.
FAQs for the comparison of Emcure Pharmaceuticals Ltd and Fabino Enterprises Ltd
Which company has a larger market capitalization, Emcure Pharmaceuticals Ltd or Fabino Enterprises Ltd?
Market cap of Emcure Pharmaceuticals Ltd is 31,850 Cr while Market cap of Fabino Enterprises Ltd is 4 Cr
What are the key factors driving the stock performance of Emcure Pharmaceuticals Ltd and Fabino Enterprises Ltd?
The stock performance of Emcure Pharmaceuticals Ltd and Fabino Enterprises Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Emcure Pharmaceuticals Ltd and Fabino Enterprises Ltd?
As of May 3, 2026, the Emcure Pharmaceuticals Ltd stock price is INR ₹1679.95. On the other hand, Fabino Enterprises Ltd stock price is INR ₹20.31.
How do dividend payouts of Emcure Pharmaceuticals Ltd and Fabino Enterprises Ltd compare?
To compare the dividend payouts of Emcure Pharmaceuticals Ltd and Fabino Enterprises Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.